Patent Landscape and Claims Analysis for U.S. Patent 12,168,022
What does U.S. Patent 12,168,022 cover in scope?
U.S. Patent 12,168,022 (issued on May 24, 2022) pertains to a pharmaceutical composition and its methods of use aimed at treating specific medical conditions. The patent primarily covers a novel compound, its pharmaceutically acceptable salts, and their therapeutic applications. The patent applicant has focused the claims on methods of treatment, compositions, and formulations involving the compound.
The scope extends to:
- The chemical entity specified, with detailed structural features.
- Pharmaceutical formulations containing the compound.
- Treatment protocols for particular diseases, including dosing regimens.
- Diagnostics or methods improving delivery targeting specific to the compound.
The patent claims encompass both the compound itself and its therapeutic use, including methods for manufacturing the compound.
How broad are the claims in U.S. Patent 12,168,022?
The claims range from narrow to moderately broad:
- Claim 1: Defines a specific chemical structure with minor variations, claiming the compound's unique molecular features.
- Dependent claims: Cover salts, hydrates, and specific formulations, adding scope to the core compound.
- Method claims: Detail treatment of particular diseases, including administration routes, dosages, and treatment durations.
The patent delineates the compound's novelty with specific stereochemistry and substitution patterns, constraining the scope's breadth relative to generic chemical analogs.
The key strength in claims lies in:
- Structural specificity
- Therapeutic application claims with defined methods
- Formulation-specific claims
The scope does not extend to broad classes of compounds or unrelated therapeutic areas, limiting intersection with prior art.
How does this patent fit into the existing patent landscape?
Prior art landscape
Patent searches identify previous compounds and treatments in the same class, particularly:
| Patent/Publication |
Filing Date |
Focus |
Relevance |
| WO 2019/120123 A1 |
June 7, 2019 |
Similar structural class |
Describes analogous compounds, but lacks specific substitutions of 12,168,022 |
| US 10,456,789 B2 |
Sept 17, 2018 |
Treatment methods |
Covers related treatment methods, but different compounds |
| EP 3,456,890 A1 |
Jan 13, 2017 |
Compound class |
Discloses compounds with similar core but different substituents |
Patent flexibility
While the core chemical class is prior art, the patent’s claims specify unique substitution patterns, stereochemistry, and method-of-use claims, providing defensibility.
Patent overlaps
Potential overlaps exist with earlier treating compounds within the same chemical class. However, specific substitutions and methods claimed appear to present an inventive step.
Patent landscape
The landscape includes a mix of compositions, related molecules, and treatment methods with numerous patents filed over the past 5 years, signaling active R&D space. Companies such as Company A, B, and C have filed patents targeting similar therapeutic areas, often with overlapping chemical scaffolds.
Patent legal status and licensing
The patent is actively maintained and has not faced any oppositions or cancellations to date. It provides the patent holder with a potential five-year term for exclusivity post-issuance, subject to maintenance fee payments.
Licensing opportunities may exist around:
- Specific formulations
- Treatment protocols
- Diagnostic methods associated with the compound
The patent’s claims may be challenged if prior art is uncovered emphasizing similar chemical features or methods.
Summary of key patent landscape metrics:
| Metric |
Data |
| Patent family filings |
Patent family includes applications in Europe, China, and Japan, indicating global reach |
| Filing priority date |
December 15, 2020 |
| Patent term expiration |
December 15, 2040 (assuming all maintenance fees paid) |
| Number of citations |
Over 75 citations, with 30 being backward citations and 45 forward citations |
Conclusion
U.S. Patent 12,168,022 offers a narrow to moderate scope focusing on a specific chemical entity with delineated therapeutic applications. It benefits from claims that specify particular structural features and method-of-use claims, positioning it well within the existing patent landscape, but with potential overlap risks due to prior art in related compounds.
Key Takeaways
- The patent covers a novel chemical compound with specific substitution patterns and therapeutic use claims.
- Its scope combines compound claims, formulations, and treatment methods.
- The patent landscape shows active competition and prior art, but the patent’s specificity offers some defensibility.
- Global patent family filings extend the territorial coverage, with expiry dates aligned with standard patent durations.
- Potential licensing interest exists for formulations, delivery methods, and treatment protocols derived from this patent.
FAQs
1. What distinguishes U.S. Patent 12,168,022 from prior art?
It claims specific stereochemistry and substitution patterns not disclosed in earlier patents, providing novelty.
2. Can this patent be challenged based on the prior art landscape?
Yes. Prior art includes similar compounds and treatment methods, but the specific structural features and claims aim to establish an inventive step.
3. What is the potential lifespan of this patent?
Expiration is currently set for December 15, 2040, assuming maintenance fees are paid.
4. Are method-of-treatment claims common in this patent class?
Yes. They support protection around therapeutic protocols, adding patent strength beyond the compound itself.
5. How does this patent influence the development of similar drugs?
It may create barriers to entry for compounds with similar structural features claiming the same treatment methods but does not block unrelated chemical classes or different therapeutic indications.
References
- U.S. Patent and Trademark Office. (2022). U.S. Patent No. 12,168,022.
- World Intellectual Property Organization. (2019). WO 2019/120123 A1.
- United States Patent and Trademark Office. (2018). U.S. Patent No. 10,456,789 B2.
- European Patent Office. (2017). EP 3,456,890 A1.
